Table 3 Characteristics of patients with Vascular Syndromes versus Encephalopathy

n

81

68

 < 0.01

_

Age, median, (IQR); mean (± SD)

62 (50–71)

57 (43.5–65)

 < 0.05

_

Female, n, (%)

46 (56.8)

41 (60.3)

0.79

_

COVID-19 severity, n, (%)

 Asymptomatic

11 (13.6)

1 (1.5)

0.12

_

 Mild

15 (18.5)

21 (30.9)

 Moderate

12 (14.8)

14 (20.6)

 Severe

9 (11.1)

9 (13.2)

 Critical

34 (42)

23 (33.8)

Δt COVID-Neuro, d, median, (IQR)

10 (6–14)

18 (12–31)

 < 0.01

_

mRS at admission, n, (%)

 ≥ 3

69 (85.2)

28 (41.1)

 < 0.01

8.21

Specific scales at admission, n, (%)

 GCS < 9

30 (37)

5 (7.4)

 < 0.01

7.41

Hospitalization due to COVID-19, n, (%)

 Yes

72 (88.9)

46 (67.6)

 < 0.01

3.83

 Needed ICU

65 (80.2)

45 (66.2)

0.07

2.07

 Needed MV

55 (67.9)

28 (41.2)

 < 0.01

3.02

 Neurocovid identified during hospitalization

42 (51.9)

27 (39.7)

0.18

_

 Neurocovid identified after extubating

6 (7.4)

20 (29.4)

 < 0.01

0.19

 Δt hospitalization, d, median, (IQR)

13 (6.5–22)

24 (11–42)

 < 0.05

In-hospital complications, n, (%)

 Co-infections

55 (67.9)

26 (38.2)

 < 0.01

2.46

 AKI with dialysis

26 (32.1)

12 (17.6)

0.06

2.20

 AKI without

22 (27.2)

10 (14.7)

0.10

_

Outcomes

 Death, n, (%)

45 (55.6)

8 (11.8)

 < 0.01

9.38

 Δt COVID-death, d, (IQR); mean (± SD)

22 (16.5—29.5)

30 (24.5—64)

 < 0.05

_

 Δt Neurocovid-death, d, median, (IQR)

11.5 (6—21.5)

18.5 (15—40.8)

0.07

_